AVXL Key Statistics, Chart & Performance
The current stock price of AVXL is 4.82 USD. In the past month the price increased by 16.43%. In the past year, price decreased by -47.67%.
AVXL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AVXL. When comparing the yearly performance of all stocks, AVXL is a bad performer in the overall market: 94.32% of all stocks are doing better.
AVXL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVXL. While AVXL has a great health rating, there are worries on its profitability.
AVXL Financial Highlights
Over the last trailing twelve months AVXL reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS decreased by -3.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.67% | ||
| ROE | -48.89% | ||
| Debt/Equity | 0 |
AVXL Forecast & Estimates
9 analysts have analysed AVXL and the average price target is 22.44 USD. This implies a price increase of 365.56% is expected in the next year compared to the current price of 4.82.
AVXL Ownership
AVXL Latest News, Press Relases and Analysis
AVXL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.48 | 392.16B | ||
| AMGN | AMGEN INC | 15.04 | 177.14B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.75 | 79.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 719.33 | 48.47B | ||
| INSM | INSMED INC | N/A | 34.86B | ||
| NTRA | NATERA INC | N/A | 33.01B | ||
| BIIB | BIOGEN INC | 10.11 | 24.84B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.03 | 20.48B | ||
| INCY | INCYTE CORP | 16.5 | 20.80B |
Related stock screener links
About AVXL
Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Company Info
ANAVEX LIFE SCIENCES CORP
630 5Th Avenue, 20Th Floor
New York City NEW YORK 10019 US
CEO: Christopher Missling
Employees: 34
Phone: 18446893939
ANAVEX LIFE SCIENCES CORP / AVXL FAQ
Can you describe the business of ANAVEX LIFE SCIENCES CORP?
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
What is the current price of AVXL stock?
The current stock price of AVXL is 4.82 USD. The price increased by 3.88% in the last trading session.
Does AVXL stock pay dividends?
AVXL does not pay a dividend.
What is the ChartMill rating of ANAVEX LIFE SCIENCES CORP stock?
AVXL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in ANAVEX LIFE SCIENCES CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AVXL.
What is ANAVEX LIFE SCIENCES CORP worth?
ANAVEX LIFE SCIENCES CORP (AVXL) has a market capitalization of 430.67M USD. This makes AVXL a Small Cap stock.